The MET-positive tumors were defined as such when at least 25% of tumor cells demonstrated membrane staining at any intensity using the MET4 monoclonal antibody and the verified MET immunohistochemistry pharmDx kit (Dako North America, Carpinteria, CA, USA). The gene discussed is MET; the disease is neoplasm.